There may not be a safe off-ramp for some taking GLP-1 drugs, study suggests
New data on GLP‑1 weight‑loss drugs such as Ozempic and tirzepatide suggest many patients regain a substantial share of lost weight and associated health benefits once they stop treatment, prompting claims there may be no “safe off‑ramp.” Commenters argue this pattern mirrors other chronic therapies and weight‑loss methods, emphasizing that obesity is largely biological, long‑term medication may be appropriate for many, and regaining some weight is still often better than never losing it. The exchange also highlights misleading media framings, overprescription concerns in parallel areas like testosterone replacement, and the need to view GLP‑1s as ongoing weight‑management tools rather than one‑time cures.
Framing of “no safe off‑ramp”
- Many commenters argue the headline is misleading: stopping GLP‑1s mostly leads to partial weight regain and loss of benefits, not some new “unsafe” state.
- Several compare this to saying there’s “no safe off‑ramp” for insulin or diets: when you stop the intervention, the original disease state tends to return.
- Others say “weight loss” drugs should be rebranded as “weight management” drugs that many will need indefinitely.
Efficacy and weight-regain data
- Commenters highlight that ~17.5% maintained ≥75% of weight loss and ~40% kept at least half, which is seen as far better than typical diet or bariatric outcomes.
- Regain is framed as “reversion to the mean”: BP, A1c, cholesterol, etc., mostly drift back with weight, similar to post‑diet experiences.
- Some argue the article underplays the key counterfactual: without GLP‑1s, most would never see those cardiovascular/metabolic improvements at all.
Comparisons to TRT and other chronic therapies
- Large subthread compares GLP‑1s to testosterone replacement therapy (TRT): both often imply lifelong use, but mechanisms differ.
- Strong criticism of “men’s vitality”/TRT clinics that allegedly overprescribe, sometimes without lab tests, creating unnecessary long‑term hormone dependence.
- Others note many chronic conditions (HIV, hypothyroidism, diabetes, schizophrenia, genetic enzyme defects) already require lifelong meds; GLP‑1s may just join that list.
Habits, agency, and obesity as disease
- Debate over whether GLP‑1s should be a temporary “kickstart” to build lasting habits versus accepting that biology dominates and most won’t maintain loss without drugs.
- Some push back against narratives that obesity is mainly a willpower failure, emphasizing evolutionary drives, environment, psychological factors, and the lack of a “cold turkey” option for food.
- Others worry about “medicalizing agency” and propose combining GLP‑1s with major life changes (new environment, therapy, even psychedelics) to reset behavior.
Side effects, neuro/psych effects, and long‑term risks
- Multiple GLP‑1 users report appetite suppression as expected; one describes reduced impulsivity but also anhedonia and blunted personality, deciding benefits weren’t worth it.
- Long‑term safety is seen as still unclear, though many note that ongoing obesity is itself highly damaging.
Cost and systemic issues
- Cost is widely seen as the main practical barrier; commenters note falling prices, generics, and compounding workarounds.
- Some speculate on societal effects: extended lifespan stressing pension systems, misaligned incentives for healthcare and pharma, and whether GLP‑1s will be treated as public‑health tools or profit streams.